Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
ENMD-2076 in triple-negative breast cancer (TNBC)
.
Show all posts
Showing posts with label
ENMD-2076 in triple-negative breast cancer (TNBC)
.
Show all posts
Tuesday, June 16, 2015
CASI initiates ENMD-2076 Phase 2 trial in Chinese patients with triple-negative breast cancer
›
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to the acquisition, development and commer...
›
Home
View web version
